JP2025504017A5 - - Google Patents

Info

Publication number
JP2025504017A5
JP2025504017A5 JP2024544889A JP2024544889A JP2025504017A5 JP 2025504017 A5 JP2025504017 A5 JP 2025504017A5 JP 2024544889 A JP2024544889 A JP 2024544889A JP 2024544889 A JP2024544889 A JP 2024544889A JP 2025504017 A5 JP2025504017 A5 JP 2025504017A5
Authority
JP
Japan
Prior art keywords
wing segment
modified oligonucleotide
compound
combination according
linked nucleosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504017A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2023/050687 external-priority patent/WO2023144750A1/en
Publication of JP2025504017A publication Critical patent/JP2025504017A/ja
Publication of JP2025504017A5 publication Critical patent/JP2025504017A5/ja
Pending legal-status Critical Current

Links

JP2024544889A 2022-01-28 2023-01-26 B型肝炎ウイルス感染症を処置するための組合せ療法 Pending JP2025504017A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263304091P 2022-01-28 2022-01-28
US63/304,091 2022-01-28
PCT/IB2023/050687 WO2023144750A1 (en) 2022-01-28 2023-01-26 Combination therapy for treating hepatitis b virus infections

Publications (2)

Publication Number Publication Date
JP2025504017A JP2025504017A (ja) 2025-02-06
JP2025504017A5 true JP2025504017A5 (cg-RX-API-DMAC10.html) 2026-02-03

Family

ID=85172882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544889A Pending JP2025504017A (ja) 2022-01-28 2023-01-26 B型肝炎ウイルス感染症を処置するための組合せ療法

Country Status (8)

Country Link
US (1) US20250092401A1 (cg-RX-API-DMAC10.html)
EP (1) EP4469161A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025504017A (cg-RX-API-DMAC10.html)
KR (1) KR20240144245A (cg-RX-API-DMAC10.html)
CN (1) CN118660704A (cg-RX-API-DMAC10.html)
AU (1) AU2023213173B2 (cg-RX-API-DMAC10.html)
CA (1) CA3243401A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023144750A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240131441A (ko) 2022-01-10 2024-08-30 오스퍼바이오 테라퓨틱스 인크. B형 간염 바이러스(hbv) 발현의 조절
CN118667808B (zh) * 2023-08-22 2025-04-18 浙江柏拉阿图医药科技有限公司 双‐Gap修饰寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3505528T1 (sl) 2011-04-21 2021-04-30 Glaxo Group Limited Modulacija izražanja virusa hepatitisa B (HBV)
AU2017285350A1 (en) * 2016-06-17 2018-12-20 F. Hoffmann-La Roche Ag Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection
US11364257B2 (en) * 2016-06-24 2022-06-21 Emory University Phosphoramidates for the treatment of hepatitis B virus
SG10202111648YA (en) * 2017-10-05 2021-11-29 Glaxosmithkline Ip Dev Ltd Chemical compounds

Similar Documents

Publication Publication Date Title
JP2022532211A5 (cg-RX-API-DMAC10.html)
JP2688113B2 (ja) 多発性硬化症の治療のための置換アデニン誘導体を含む薬学的組成物
US11939581B2 (en) Methods and compositions for targeting PD-L1
JPH09504785A (ja) 抗b型肝炎ウイルス活性を有するヌクレオシド
CN100400045C (zh) 基于核酸的化合物及其使用方法
JP2004505889A (ja) ヌクレオシド化合物およびその使用
JP2015528449A5 (cg-RX-API-DMAC10.html)
JP2001513514A (ja) 少なくとも1種の二重鎖RNA(dsRNA)を、少なくとも1種の抗ウイルス剤と組合せて含有する製品
JP2022515778A5 (cg-RX-API-DMAC10.html)
JP2004525142A5 (cg-RX-API-DMAC10.html)
JP2011079840A (ja) B型肝炎治療のための組合せ療法
US20240052350A1 (en) Oligonucleotide and use thereof against hepatitis b virus and hepatitis d virus
TW202140789A (zh) 靶向pd—l1之方法及組合物
TW202103698A (zh) 用於治療b型肝炎病毒感染之組合療法
TW202207950A (zh) 治療d型肝炎病毒感染之組合物及方法
JP2023543898A5 (cg-RX-API-DMAC10.html)
CN114533739A (zh) 核苷类似物在制备预防或治疗胃肠道疾病药物中的应用
JP2024544532A5 (cg-RX-API-DMAC10.html)
TW202146011A (zh) 治療b型肝炎病毒感染之組合療法
JP2025511096A5 (cg-RX-API-DMAC10.html)
JP2023520405A5 (cg-RX-API-DMAC10.html)
TW202126304A (zh) 使用核心蛋白異位調節劑治療hbv感染之方法
JP2002515892A (ja) サイトカインが関係する疾患治療法
KR20210020104A (ko) 면역 반응 촉진
JP2002526441A (ja) 抗ウイルス性組合せ製剤